Advantages and Pitfalls of Fructosamine and Glycated Albumin in the Diagnosis and Treatment of Diabetes
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
The efficient diagnosis and accurate monitoring of diabetic patients are cornerstones for reducing the risk of diabetic complications. The current diagnostic and prognostic strategies in diabetes are mainly based on two tests, plasma (or capillary) glucose and glycated hemoglobin (HbA1c). Nevertheless, these measures are not foolproof, and their clinical usefulness is biased by a number of clinical and analytical factors. The introduction of other indices of glucose homeostasis in clinical practice such as fructosamine and glycated albumin (GA) may be regarded as an attractive alternative, especially in patients in whom the measurement of HbA1c may be biased or even unreliable. These include patients with rapid changes of glucose homeostasis and larger glycemic excursions, and patients with red blood cell disorders and renal disease. According to available evidence, the overall diagnostic efficiency of GA seems superior to that of fructosamine throughout a broad range of clinical settings. The current method for measuring GA is also better standardized and less vulnerable to preanalytical variables than those used for assessing fructosamine. Additional advantages of GA over HbA1c are represented by lower reagent cost and being able to automate the GA analysis on many conventional laboratory instruments. Although further studies are needed to definitely establish that GA can complement or even replace conventional measures of glycemic control such as HbA1c, GA may help the clinical management of patients with diabetes in whom HbA1c values might be unreliable.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hyperglycemia and adverse pregnancy outcomes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707943 · Cited by 5,563
Global estimates of diabetes prevalence for 2013 and projections for 2035
Guariguata, L., Whiting, D. R., Hambleton, I., Beagley, J., Linnenkamp, U., & Shaw, J. E. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2013.11.002 · Cited by 4,642 · cited 1×
“Worldwide, as many as 592 million individuals may be affected by diabetes in 2035, a remarkable 55% increase in prevalence over the next 2 decades.(1) Due to its high global prevalence and severe, frequently life-threatening complications (eg, retinopathy, nephropathy, neuropathy, cardiovascular disease), diabetes mus…”
BackgroundStandards of medical care in diabetes—2014
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc14-s014 · Cited by 4,572
The glycation of albumin: Structural and functional impacts
Rondeau, P., & Bourdon, E. (2011) · Biochimie · doi:10.1016/j.biochi.2010.12.003 · Cited by 433 · cited 2×
“As a consequence of the greater susceptibility to glycation of albumin and other plasma proteins compared to intracellular proteins such as hemoglobin, the blood levels of GA exhibit a broader fluctuation than those of HbA1c, thus allowing an earlier detection of rapid changes of blood glucose.(12) Accordingly, the me…”
BackgroundComparison of glycated albumin and hemoglobin A1c levels in diabetic subjects on hemodialysis
Peacock, T. P., Shihabi, Z. K., Bleyer, A. J., Dolbare, E. L., Byers, J. R., Knovich, M. A., Calles-Escandon, J., Russell, G. B., & Freedman, B. I. (2008) · Kidney International · doi:10.1038/ki.2008.25 · Cited by 323
Clinical impact of glycated albumin as another glycemic control marker
Koga, M., & Kasayama, S. (2010) · Endocrine Journal · doi:10.1507/endocrj.k10e-138 · Cited by 290 · cited 1×
“In these conditions the use of alternative markers may overcome the drawbacks of HbA1c, by providing additional information about shorter-term glycemic control.(28) In particular, the measurement of fructosamine and GA has been proposed to improve diagnosis and monitoring of diabetes, alone or in combination with HbA1…”
BackgroundSelvin, E., Rawlings, A. M., Grams, M., Klein, R., Sharrett, A. R., Steffes, M., & Coresh, J. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70199-2 · Cited by 262
Relationship between assays of glycemia in diabetic subjects with advanced chronic kidney disease
Freedman, B. I., Shihabi, Z. K., Andries, L., Cardona, C. Y., Peacock, T. P., Byers, J. R., Russell, G. B., Stratta, R. J., & Bleyer, A. J. (2010) · American Journal of Nephrology · doi:10.1159/000287561 · Cited by 90
Cited by
Update on biomarkers of glycemic control
Krhač, M., & Lovrenčić, M. V. (2019) · World Journal of Diabetes · doi:10.4239/wjd.v10.i1.1 · Cited by 93
Zelnick, L. R., Batacchi, Z. O., Ahmad, I., Dighe, A., Little, R. R., Trence, D. L., Hirsch, I. B., & de Boer, I. H. (2020) · Diabetes Care · doi:10.2337/dc20-0915 · Cited by 55
Nutrition Care Process Model Approach to Surgical Prehabilitation in Oncology
Gillis, C., Hasil, L., Kasvis, P., Bibby, N., Davies, S. J., Prado, C. M., West, M. A., & Shaw, C. (2021) · Frontiers in Nutrition · doi:10.3389/fnut.2021.644706 · Cited by 46
Metadata
- Authors
- Danese, E., Montagnana, M., Nouvenne, A., & Lippi, G.
- Venue
- Journal of Diabetes Science and Technology
- Publisher
- SAGE Publications
- Published
- 2015-01-14
- Volume
- 9
- Issue
- 2
- Pages
- 169-176
- ISSN
- 1932-2968 (ISSN-L)
- OpenAlex
- W2099794801
- Cited by
- 238
- References
- 8
- FWCI
- 14.18
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Advantages and Pitfalls of Fructosamine and Glycated Albumin in the Diagnosis and Treatment of Diabetes. https://app.cochat.ai/papers/10.1177/1932296814567227
- The paper
- Danese, E., Montagnana, M., Nouvenne, A., & Lippi, G. (2015). Advantages and Pitfalls of Fructosamine and Glycated Albumin in the Diagnosis and Treatment of Diabetes. Journal of Diabetes Science and Technology. https://doi.org/10.1177/1932296814567227
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.